An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, X-linked disease, connective tissue disorder, cutaneous mucinosis, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, inherited neurodegenerative disorder, intellectual disability, lysosomal storage disease, metabolic disease, mucopolysaccharidosis, mucopolysaccharidosis type 2, nervous system disorder	Enrolling by invitation	Phase 3	2026-01-21		NCT05594992

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
JCR Pharmaceuticals Co., Ltd.	8

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Children's Hospital of Philadelphia	Philadelphia	United States	434
Hospital de Clínicas de Porto Alegre	Porto Alegre	Brazil	12
Hospital Sant Joan de Déu	Barcelona	Spain	11
Hospital Universitario Austral	Buenos Aires	Argentina	4
Hôpital Femme Mère Enfant	Bron	France	5
Instituto de Genética e Erros Inatos do Metabolismo	São Paulo	Brazil	2
Osp. Pediatrico Bambino Gesù, IRCCS	Rome	Italy	2
UCSF Benioff Children's Hospital Oakland	Oakland	United States	85
Universitätsklinikum Hamburg-Eppendorf	Hamburg	Germany	31
Uniwersytecki Szpital Dziecięcy	Krakow	Poland	2